{
  "slug": "orsobio",
  "name": "Orsobio",
  "description": "OrsoBio is a biotechnology company focused on developing novel oral therapeutics for severe metabolic disorders, including severe hypertriglyceridemia (SHTG), metabolic dysfunction–associated steatotic liver disease (MASLD)/MASH, and obesity. The company is advancing drugs like TLC-2716 and TLC-6740 through clinical trials.",
  "url": "https://optimly.ai/brand/orsobio",
  "websiteUrl": "https://fiercebiotech.com/",
  "logoUrl": "https://logo.clearbit.com/fiercebiotech.com",
  "baiScore": 30,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Pharmaceutical Companies",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-09-14T15:07:46.946Z",
  "verifiedVitals": {
    "website": "https://fiercebiotech.com",
    "category": "biotech",
    "what_it_does": "Develops experimental oral drugs for severe metabolic disorders, including severe hypertriglyceridemia (SHTG), metabolic dysfunction–associated steatotic liver disease (MASLD), MASH, and obesity.",
    "primary_audience": "Patients with severe hypertriglyceridemia (SHTG), metabolic dysfunction–associated steatotic liver disease (MASLD), MASH, and obesity.",
    "core_product": "TLC-2716 (a liver X receptor (LXR) inverse agonist) and TLC-6740 (a liver-targeted mitochondrial protonophore).",
    "parent_ownership": null
  },
  "intentTags": {
    "problemIntents": [
      "Severe hypertriglyceridemia (SHTG)",
      "Metabolic dysfunction–associated steatotic liver disease (MASLD)",
      "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "Obesity",
      "Elevated remnant cholesterol",
      "Excessive lipid production"
    ],
    "solutionIntents": [
      "Oral drug development for metabolic disorders",
      "LXR inverse agonist therapy",
      "Mitochondrial protonophore therapy",
      "Reduction of fasting triglycerides",
      "Improvement of hepatic fat",
      "Weight management solutions",
      "Therapeutic options for severe metabolic disorders"
    ],
    "evaluationIntents": [
      "Clinical trial results",
      "Phase 2a data analysis",
      "Phase 2b study planning",
      "Drug safety and tolerability assessment",
      "Efficacy of metabolic disorder treatments",
      "Biotech financing and partnerships",
      "LXR inverse agonism validation"
    ]
  },
  "businessProfileClaims": [],
  "timestamp": 1789830805006
}